Mideast War Won't Shut Down the Silicon Road
The big theme in Asian supply chains over the past decade has been relocation. Entire industries have sought to pare their reliance on China by shifting manufacturing to other low-cost destinations like Vietnam and India. Japanese carmakers and Indian pharmaceutical firms have chosen Mexico to be closer to American demand. More recently, however, a new route is emerging — from Asia to the Middle East.
Speculation that the US is on the verge of joining Israel's attack on Iran may unsettle business leaders' current plans and delay activity along the corridor. However, as long as hostilities don't spiral into a catastrophic event, such as the closing of the all-important Strait of Hormuz to shipping, they are unlikely to derail the economic case for a reprisal of the historic Silk Road.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Investors in Engtex Group Berhad (KLSE:ENGTEX) have seen respectable returns of 68% over the past five years
When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking involves risks (and requires diversification) it can also provide excess returns. To wit, the Engtex Group Berhad share price has climbed 58% in five years, easily topping the market return of 6.2% (ignoring dividends). So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. While Engtex Group Berhad made a small profit, in the last year, we think that the market is probably more focussed on the top line growth at the moment. Generally speaking, we'd consider a stock like this alongside loss-making companies, simply because the quantum of the profit is so low. It would be hard to believe in a more profitable future without growing revenues. In the last 5 years Engtex Group Berhad saw its revenue grow at 8.5% per year. That's a pretty good long term growth rate. While the share price has beat the market, compounding at 10% yearly, over five years, there's certainly some potential that the market hasn't fully considered the growth track record. The key question is whether revenue growth will slow down, and if so, how quickly. There's no doubt that it can be difficult to value pre-profit companies. You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image). It's probably worth noting that the CEO is paid less than the median at similar sized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. So it makes a lot of sense to check out what analysts think Engtex Group Berhad will earn in the future (free profit forecasts). When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. We note that for Engtex Group Berhad the TSR over the last 5 years was 68%, which is better than the share price return mentioned above. And there's no prize for guessing that the dividend payments largely explain the divergence! While the broader market lost about 6.9% in the twelve months, Engtex Group Berhad shareholders did even worse, losing 12% (even including dividends). However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. On the bright side, long term shareholders have made money, with a gain of 11% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 4 warning signs with Engtex Group Berhad (at least 1 which shouldn't be ignored) , and understanding them should be part of your investment process. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Malaysian exchanges. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
SURGLASSES Launches the World's First AI Anatomy Table
Asclepius AI Table sets a new benchmark for intelligent, hands-on medical learning. TAIPEI, June 19, 2025 /PRNewswire/ -- Surglasses Inc. today announced the launch of the Asclepius AI Table, the world's first anatomy table with fully integrated AI instruction — a groundbreaking device that brings real-time intelligence and immersive interaction into medical and veterinary education. Unlike traditional systems that rely on external software or passive content, the Asclepius AI Table is a self-contained, AI-enhanced teaching platform. Two built-in digital instructors respond to voice and text in real time, offering guided instruction, anatomical explanations, and adaptive learning based on user input. The system is ready to use out of the box, requiring no technical setup or training, making it ideal for classrooms, labs, and interactive demonstrations. The table features eight deeply integrated modules designed to meet the diverse demands of modern medical and veterinary curricula. Students can freely explore high-resolution 3D virtual cadavers, perform open-ended digital dissection, and examine body structures from any angle. For radiological learning, the table enables ultra-fast 3D reconstruction and visualization of CT scans through a built-in DICOM viewer, with multiple rendering presets for efficient analysis. In the field of pathology, the Histopathology Explorer launches in seconds and includes a large collection of ultra-HD slides, while also supporting custom slide uploads. Movement and biomechanics are covered through the Kinesiology Module, which presents dozens of animated human motion models for understanding joint mechanics and musculoskeletal interactions. Additional tools include CTRender, a powerful engine for importing and manipulating DICOM files; a real-time ultrasound simulator that supports procedural training using clinical data; and a robust veterinary anatomy library with anatomical models for a wide range of species — supporting both human and animal education in a unified environment. The Embryology Timeline rounds out the system, offering a vivid 3D visualization of human development from fertilization to birth — helping students connect macro-level anatomy with developmental biology in a way that textbooks alone cannot achieve. Across all modules, the embedded AI instructors serve as constant companions: answering questions, guiding exploration, and supporting instructors and students alike with precision and immediacy. "The Asclepius AI Table is the first of its kind — an anatomy table that doesn't just show, it teaches," said Dr. Min-Liang Wang, founder and CEO of Surglasses Inc. "By embedding intelligent guidance directly into the table, we're transforming how anatomy and clinical science are taught — making learning faster, deeper, and more intuitive." Now Available for Global Distribution Already generating strong interest from medical schools, teaching hospitals, and veterinary institutions, the Asclepius AI Table is now available worldwide. Surglasses welcomes demo requests, academic partnerships, and distribution inquiries. Media ContactMarketing info@ nina@ About Surglasses Inc. Surglasses Inc. develops next-generation solutions for medical training and surgical navigation. Its flagship technologies — including the Caduceus S AR spinal navigation system and the Asclepius AI Table — are redefining how healthcare professionals learn, plan, and perform with greater confidence and clarity. View original content to download multimedia: SOURCE SURGLASSES
Yahoo
36 minutes ago
- Yahoo
Fidelity Fund Bets on Midcaps Saying Worst of Tariffs Is Over
(Bloomberg) -- Financial markets have seen the worst of Donald Trump's tariff threats, helping make midcap stocks an attractive buy as the outlook improves, according to a Fidelity International money manager. Security Concerns Hit Some of the World's 'Most Livable Cities' JFK AirTrain Cuts Fares 50% This Summer to Lure Riders Off Roads Taser-Maker Axon Triggers a NIMBY Backlash in its Hometown NYC Congestion Toll Cuts Manhattan Gridlock by 25%, RPA Reports How E-Scooters Conquered (Most of) Europe Japan, Germany and China midcaps account for about 11% of Fidelity's growth and income fund — making them some of the strategy's highest conviction trades, said George Efstathopoulos. In contrast, there was 'very limited exposure' to such stocks about 18 months ago. 'The worst of the shock is behind us with Liberation Day,' said Efstathopoulos, referring to the April 2 US tariff announcement that triggered a global equity rout. 'The numbers that were recorded on that day were the worst it can get.' Fidelity is maintaining its conviction even as investors gear up for the end of the 90-day tariff truce on July 8, when reciprocal levies will take effect if nations fail to reach a trade deal with the US. Tensions in the Middle East may also pose a major test for stock markets, with Trump to decide within two weeks whether to strike Iran as the conflict with Israel escalates. For now, many of Efstathopoulos' bets have paid off, and he's convinced they remain a buy. The MSCI Japan Mid Cap Index has gained more than 4% since April 2, while Germany's DAX Mid-Cap gauge has risen almost 6%. A similar index of Chinese stocks advanced about 0.5% during that period. The money manager has had some exposure to Chinese and Japanese stocks since the second half of last year, while it scooped up German midcaps in March shortly after the government announced a historic spending package. 'In a world of trade disruption, disruption of globalization, I think it makes sense to focus on more domestic revenue generation,' said Efstathopoulos, who oversees about $3 billion from Singapore. German equities should advance because they're poised to benefit from a landmark shift toward more fiscal spending and concentrated exposure to domestic demand, he said. Meanwhile, Japan is undergoing a once-in-a-generation shift with 'good inflation' rippling across the economy, and mid-sized companies are likely to benefit most from rising domestic consumption, said Efstathopoulos. Fidelity likes Chinese firms due to prospects of further fiscal stimulus and limited risk of losses, thanks in part to factors like state-backed investors swooping into markets to prop up stock prices. Efstathopoulos helps oversee Fidelity's global multi-asset growth and income fund that's returned a cumulative 11% over the past five years to May, according to a company factsheet. RBI's Liquidity Boost to Propel Indian Small Caps: Taking Stock Ken Griffin on Trump, Harvard and Why Novice Investors Won't Beat the Pros Is Mark Cuban the Loudmouth Billionaire that Democrats Need for 2028? The US Has More Copper Than China But No Way to Refine All of It Can 'MAMUWT' Be to Musk What 'TACO' Is to Trump? How a Tiny Middleman Could Access Two-Factor Login Codes From Tech Giants ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
